Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1462 • 2013 ACR/ARHP Annual Meeting
Unmasking The Tolerability Of Methotrexate In Patients With Rheumatoid and Psoriatic Arthritis: A Retrospective Review Of Discontinuation From a Large UK Cohort
Andra Negoescu¹, Elena Nikiphorou², Anshuman P. Malaviya³, Andrew Badcock³, John D. Fitzpatrick^3,4, Calum T. Goudie^3,4 and Andrew J. Ostor³, ¹Rheumatology, Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge, United Kingdom, ²Rheumatology, Addenbrooke's Hospital, Cambridge, United Kingdom, ³Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge, United Kingdom, ⁴University of Cambridge Medical School, Cambridge, United Kingdom
Background/Purpose: Due to its efficacy and perceived safety, methotrexate (MTX) has become the foundation disease-modifying drug for rheumatoid (RA) and psoriatic arthritis (PsA) however…
Abstract Number: 301 • 2013 ACR/ARHP Annual Meeting
Arthritis and Nail Involvement In Patients With Plaque-Type Psoriasis
Odirlei Andre Monticielo¹, Karen Regina Rosso Schons², Cristiane Faccin Knob², Walter Neumaier², Maristela de Oliveira Beck² and André Avelino Costa Beber², ¹Department of Internal Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ²Universidade Federal de Santa Maria, Santa Maria, Brazil
Background/Purpose: Psoriasis is a chronic disease that presents in individuals of all ages, affecting skin, nails and joints. Nail changes are estimated to be present…
Abstract Number: 1367 • 2013 ACR/ARHP Annual Meeting
Performance Of a Two-Step Latent Tuberculosis Screening Algorithm In Patients With Rheumatoid Arthritis, Psoriatic Arthritis Or Ankylosing Spondylitis Prior To Treatment With Tumor Necrosis Alpha Inhibitors: Prospective Observational Data From The Biorx.Si Registry
ŽIga Rotar¹ and Matija Tomsic², ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Department of Rheumatology, University Medical Centre Ljubjana, Ljubljana, Slovenia
Background/Purpose: Reactivation of latent tuberculosis infection (LTBI) is of concern in patients treated with TNFi. Conversely, TB chemoprophylaxis (CP) is time consuming, delays the initiation…
Abstract Number: 310 • 2013 ACR/ARHP Annual Meeting
Long-Term Safety and Tolerability Of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, In Patients With Psoriatic Arthritis: Pooled Safety Analysis Of Three Phase 3, Randomized, Controlled Trials
Philip J. Mease¹, Arthur Kavanaugh², Dafna D. Gladman³, Adewale O. Adebajo⁴, Juan J. Gomez-Reino⁵, Jürgen Wollenhaupt⁶, Maurizio Cutolo⁷, Georg Schett⁸, Eric Lespessailles⁹, Kamal Shah¹⁰, ChiaChi Hu¹⁰, Randall M. Stevens¹⁰, Christopher J. Edwards¹¹ and Charles A. Birbara¹², ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²University of California San Diego, San Diego, CA, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, United Kingdom, ⁵Rheumatology, Hospital Clinico Universitario, Santiago, Spain, ⁶Schön Klinik Hamburg Eilbek, Hamburg, Germany, ⁷University of Genova, Genova, Italy, ⁸Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁹University of Orléans, Orléans, France, ¹⁰Celgene Corporation, Warren, NJ, ¹¹University of Southampton, Southampton, United Kingdom, ¹²University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate inflammatory mediators. PALACE 1, 2, and 3 compared the efficacy and safety of…
Abstract Number: 2561 • 2012 ACR/ARHP Annual Meeting
Switching Between TNF-Inhibitors in Psoriatic Arthritis: Data From the NOR-DMARD Study
Karen M. Fagerli¹, Elisabeth Lie², Désirée van der Heijde³, Marte S. Heiberg⁴, Åse S. Lexberg⁵, Knut Mikkelsen⁶, Erik Rødevand⁷, Synnøve Kalstad⁸ and Tore K. Kvien¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology, Diakonhjemmet hospital, Oslo, Norway, ⁵Department of Rheumatology, Vestre Viken, Drammen, Norway, ⁶Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ⁷Dept. of Rheumatology, St. Olavs Hospital, Trondheim, Norway, ⁸Dept. of Rheumatology, University Hospital of Northern Norway, Tromsø, Norway
Background/Purpose: Although TNF-inhibitors (TNFi) have proven efficacy in psoriatic arthritis (PsA), some patients do not respond to or do not tolerate their first TNFi. The…
Abstract Number: 531 • 2012 ACR/ARHP Annual Meeting
Developmen and Validation of a New Instrument to Asess Health Related Quality of Life in Psoriasis Arthritis: The Vitacora Questionnaire
Juan Carlos Torre-Alonso¹, J. Santos-Rey², JM Ruiz-Martin³, P. Valdazo-De Diego⁴, Mireia Moreno⁵ and Juan-Antonio Fernández⁶, ¹Unit Rheumatology, Hospital Monte Naranco, Oviedo, Spain, ²Rheumatology, Toledo, Spain, ³Rheumatology, Viladecans, Spain, ⁴Rheumatology, Zamora, Spain, ⁵Rheumatology, Corporació Sanitària Parc Taulí, Sabadell, Spain, ⁶MP, Oviedo, Spain
Background/Purpose: To develop and validate a specific questionnaire to measure health-related quality of life (HRQoL) in adults with psoriasis arthritis (PA) for use in clinical…
Abstract Number: 2562 • 2012 ACR/ARHP Annual Meeting
Ustekinumab in Patients with Active Psoriatic Arthritis: Results of the Phase 3, Multicenter, Double-Blind, Placebo-Controlled Psummit I Study
Arthur Kavanaugh¹, Iain B. McInnes², Alice B. Gottlieb³, Lluis Puig⁴, Proton Rahman⁵, Christopher T. Ritchlin⁶, Shu Li⁷, Yuhua Wang⁸, Alan Mendelsohn⁹ and Mittie K. Doyle⁷, ¹UCSD School of Medicine, La Jolla, CA, ²University of Glasgow, Glasgow, United Kingdom, ³Tufts Medical Center, Boston, MA, ⁴Universitat Autònoma de Barcelona, ⁵Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁶Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁷Janssen Research & Development, LLC, Spring House, PA, ⁸Janssen Research & Development, LLC., Spring House, PA, ⁹Immunology, Janssen Research & Development, LLC, Spring House, PA
Ustekinumab in Patients with Active Psoriatic Arthritis: Results of the Phase 3, Multicenter, Double-blind, Placebo-Controlled PSUMMIT I StudyBackground/Purpose: To assess efficacy and safety of ustekinumab…
Abstract Number: 536 • 2012 ACR/ARHP Annual Meeting
Psoriasis and Psoriatic Arthritis in a Diverse Ethnic Cohort
Gail S. Kerr¹, Seema Qaiyumi², John S. Richards², Chesahna Kindred³, Sean A. Whelton⁴ and Florina M. Constantinescu⁵, ¹Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ²Rheumatology Section, Washington DC VA and Georgetown University, Washington, DC, ³Division of Dermatology, Howard University Hospital, Washington, DC, ⁴Division of Rheumatology, Georgetown University, Washington, DC, ⁵Rheumatology, Washington Hospital Center, Washington, DC
Background/Purpose: Few clinical studies describe psoriasis (PSO) and psoriatic arthritis (PsA) in ethnic minority groups. Previous patient-reported data show PSO/PsA to be less frequent in…
Abstract Number: 2491 • 2012 ACR/ARHP Annual Meeting
IL-17 Expression Is Low in Psoriatic Arthritis Synovium Compared to Expression in Matched Skin Lesions
Jennifer Belasco¹, Hiroshi Mitsui¹, Mayte Suarez-Farinas¹, James S. Louie², Nathan Wei³, Nicholas Gulati¹ and James G. Krueger¹, ¹Krueger Laboratory, The Rockefeller University, New York, NY, ²Rheumatology, UCLA School of Medicine, Los Angeles, CA, ³Arthritis Treatment Center, Frederick, MD
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory joint disease associated with psoriasis. It is known that treatment modalities are not equally effective for both skin…
Abstract Number: 537 • 2012 ACR/ARHP Annual Meeting
The Association of alpha7 Nicotinic Acetylcholine Receptor Polymorphisms with Psoriatic Arthritis and Its Interaction with Smoking
Lihi Eder¹, Vinod Chandran², Fawnda Pellett³, Remy Pollock⁴, Fatima Abji⁵, Adele Carty⁶, Sutharshini Shanmugarajah⁵, Cheryl Rosen⁷ and D. D. Gladman⁸, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁵Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁶Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁷Division of Dermatology, University of Toronto, Toronto western Hospital, Toronto, ON, Canada, ⁸Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Alpha7 nicotinic acetylcholine receptor (CHRNA7) is an ion channel that is gated by the binding of nicotinic ligands. Nicotine interacts with CHRNA7 leading to…
Abstract Number: 2223 • 2012 ACR/ARHP Annual Meeting
Dysregulation of Chromatin Modification Enzymes in Psoriatic Arthritis
Remy Pollock¹, Fawnda Pellett², Vinod Chandran³ and Dafna D. Gladman⁴, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁴Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Chromatin modification enzymes regulate gene expression by altering the accessibility of promoters to transcription factors. Several of these enzymes are dysregulated in rheumatoid arthritis,…
Abstract Number: 108 • 2012 ACR/ARHP Annual Meeting
Disparity Between Sonographic and Clinical Criteria of Remission in Psoriasis Arthritis
Christian Dejaco¹, Rusmir Husic², Judith Gretler³, Winfried B. Graninger⁴ and Josef Hermann², ¹Rheumatology, Southend University Hospital, Westcliff-on-Sea, United Kingdom, ²Rheumatology, Medical University Graz, Graz, Austria, ³Med Univ Klinik Graz, Auenbruggerplatz 15, Graz, Austria, ⁴Internal medicine/Rheumatology and Immunology, Medical University Graz, Graz, Austria
Background/Purpose: To compare ultrasound and clinical definitions of remission in psoriasis arthritis (PsA). Methods: Prospective study of 70 consecutive PsA patients [mean age 51.1 (±SD…
Abstract Number: 2228 • 2012 ACR/ARHP Annual Meeting
The Caspar Classification Criteria and Response to TNF Blockade in Rheumatologists Practice: A Large Observational Cohort Study
Burkhard Moller¹, Almut Scherer², J. Dudler³, Bettina Weiss⁴, Nikhil Yawalkar⁵ and Peter M. Villiger⁶, ¹Rheumatology, Inselspital University Hospital, Bern, Switzerland, ²SCQM Foundation, Zurich, Switzerland, ³Rheumatology, Cantonal Hospital Fribourg, Fribourg, Switzerland, ⁴Division of Rheumatology, Balgrist University Hospital, Zurich, Switzerland, ⁵Dermatology, MD, Bern, Switzerland, ⁶Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland
The CASPAR classification criteria and response to TNF blockade in Rheumatologists' practice: A large observational cohort study Burkhard Möller, Almut Scherer, Jean Dudler, Bettina Weiss,…
Abstract Number: 114 • 2012 ACR/ARHP Annual Meeting
US Examination of Wrists and Hands: A Comparison Between Rheumatoid Arthritis and Psoriatic Arthritis
Andrea Delle Sedie¹, Elisa Cioffi¹, Linda Carli², Elena Sardano³, Stefano Bombardieri¹ and Lucrezia Riente¹, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Department of Clinical and Experimental Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ³Immunology Unit, University of Pisa, Immunology Unit, University of Pisa, Italy
Background/Purpose: very little is known about the differences in joint and periarticular structure involvement in rheumatoid or psoriatic arthritis (PsA). The main pathological features detected…
Abstract Number: 2058 • 2012 ACR/ARHP Annual Meeting
Differences in Psychological Characteristics Between Patients with Rheumatoid and Psoriatic Arthritis
Panagiota Tsitsi¹, Athina Theodoridou¹, Foteini Lada¹, Konstantinos Papanikolaou², Despina Dimopoulou¹, Georgios Garyfallos³, Alexios Benos⁴ and Alexandros Garyfallos⁵, ¹4th Department of Internal Medicine,Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece, ²Psychiatric Hospital of Petra Olympus, Katerini, Greece, Katerini, Greece, ³2nd Department of Psychiatry, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece, ⁴Department of Hygiene, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece, ⁵4th Department of Internal Medicine, Aristotle University, Hippocratio Hospital, 4th Department of Internal Medicine, Aristotle University, Hippocratio Hospital, Thessaloniki, Greece
Background/Purpose: Both rheumatoid (RA) and psoriatic arthritis (PsA) seem to have a negative impact on patients’ psychological status mostly due to the chronic character of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].